Hereditary Transthyretin-mediated (hATTR) Amyloidosis
0
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
RNA Therapeutic
1100%
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Alnylam PharmaceuticalsCAMBRIDGE, MA
1 programPatisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance ProgramN/ARNA Therapeutic1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Alnylam PharmaceuticalsPatisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
Clinical Trials (1)
Total enrollment: 10 patients across 1 trials
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
Start: Aug 2020Est. completion: Oct 203010 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 10 patients
1 companies competing in this space